SAFETY PROFILE SEEN during PIVOTAL STUDIES1
Table summarizing adverse event data from PSOARING 1 and PSOARING 2 studies.
  • Minimal systemic absorption: Up to 96% of patients (N=187) were below the quantifiable limit (<50 pg/mL) at week 127,8
  • Low rates of treatment discontinuation: 2.8% of patients discontinued treatment due to folliculitis and 2.9% discontinued treatment due to contact dermatitis1,6
  • Study discontinuation: Of those randomized to receive VTAMA cream, 1.8% and 0.9% withdrew from the study due to folliculitis, 1.5% and 2.0% withdrew due to contact dermatitis in PSOARING 1 and 2, respectively
WELL TOLERATED, EVEN IN SENSITIVE SKIN AREAS

VTAMA® (tapinarof) cream, 1% is a versatile treatment option with no label restrictions on topical, external use to the affected skin areas. It was well tolerated even on sensitive skin areas like the face, neck, intertriginous areas, inframammary areas, axillae, genitalia, and anal crux. VTAMA cream is not for oral, ophthalmic, or intravaginal use.1,4

Click on the buttons below to see how VTAMA cream was tolerated in even the most sensitive skin areas
VTAMA cream tolerability data
In pivotal studies of VTAMA cream, the tolerability score was below mild on all assessed areas of sensitive skin.
PSOARING 1 and PSOARING 2 Tolerability data: Face4,6-8
Chart illustrating high tolerability of VTAMA® cream on the face, from PSOARING 1 and PSOARING 2 pivotal studies.
*Combined n across treatment groups and studies for patients who completed the assessment at the week 2 visit. The n value differed across visits.
PSOARING 1 and PSOARING 2 Tolerability data: NECK4,6-8
Chart illustrating high tolerability of VTAMA® cream on the neck, from PSOARING 1 and PSOARING 2 pivotal studies.
*Combined n across treatment groups and studies for patients who completed the assessment at the week 2 visit. The n value differed across visits.
PSOARING 1 and PSOARING 2 Tolerability data: INTERTRIGINOUS AREAS4,6-8
Chart illustrating high tolerability of VTAMA® cream on intertriginous areas, from PSOARING 1 and PSOARING 2 pivotal studies.
*Combined n across treatment groups and studies for patients who completed the assessment at the week 2 visit. The n value differed across visits.
PSOARING 1 and PSOARING 2 Tolerability data: INFRAMAMMARY AREAS4,6-8
Chart illustrating high tolerability of VTAMA® cream on inframammary areas, from PSOARING 1 and PSOARING 2 pivotal studies.
*Combined n across treatment groups and studies for patients who completed the assessment at the week 2 visit. The n value differed across visits.
PSOARING 1 and PSOARING 2 Tolerability data: Axillae4,6-8
Chart illustrating high tolerability of VTAMA® cream on axillae, from PSOARING 1 and PSOARING 2 pivotal studies.
*Combined n across treatment groups and studies for patients who completed the assessment at the week 2 visit. The n value differed across visits.
PSOARING 1 and PSOARING 2 Tolerability data: Genitalia4,6-8
Chart illustrating high tolerability of VTAMA® cream on genitalia, from PSOARING 1 and PSOARING 2 pivotal studies.
*Combined n across treatment groups and studies for patients who completed the assessment at the week 2 visit. The n value differed across visits.
PSOARING 1 and PSOARING 2 Tolerability data: Anal crux4,6-8
Chart illustrating high tolerability of VTAMA® cream on anal crux, from PSOARING 1 and PSOARING s 2 pivotal studies.
*Combined n across treatment groups and studies for patients who completed the assessment at the week 2 visit. The n value differed across visits.
What would you like to see next?